EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC0

Alternative approaches for monitoring and evaluation of lymphatic filariasis following mass drug treatment with ivermectin, diethylcarbamazine and albendazole in East New Britain Province, Papua New Guinea

Krufinta Bun, Benedict Mode, Melinda Susapu, Joyceline Salo, Catherine Bjerum, Michael Payne, Daniel Tisch, Makoto Sekihara, Emanuele Giorgi, Gary J Weil, Peter U Fischer, Leanne Robinson und 2 weitere

PLOS Neglected Tropical Diseases · 2025

DOI: 10.1371/journal.pntd.0012128 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift PLOS Neglected Tropical Diseases, 2025. Verfasst von Krufinta Bun und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Center for Global Health and Disease, Case Western Reserve University, Cleveland, Ohio, United States of America. Hauptthemen laut MEDLINE: Albendazole, Diethylcarbamazine, Elephantiasis, Filarial, Filaricides. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC0). Gefördert von: NCATS NIH HHS, Bill and Melinda Gates Foundation, National Health and Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

WHO recommends two annual rounds of mass drug administration (MDA) with ivermectin, diethylcarbamazine, and albendazole (IDA) for lymphatic filariasis (LF) elimination in treatment naïve areas that are not co-endemic for onchocerciasis such as Papua New Guinea (PNG). Whether two rounds of MDA are necessary or sufficient and the optimal sampling strategies and endpoints for stopping MDA remain undefined. Methods and findings Two cross-sectional studies were conducted at baseline (N = 49 clusters or villages) and 12 months after mass drug administration (MDA) with IDA (N = 47 villages) to assess lymphatic filariasis (LF) by circulating filarial antigenemia (CFA) and microfilariae (Mf). Before MDA, children aged 6–9 years (N~50) and those ≥ 10 years (N~50) in each village were randomly sampled. Before MDA, the population mean prevalence of LF in East New Britain Province (ENBP), Papua New Guinea, was estimated using population proportionate sampling (PPS, N = 30) to be 59/2,561 (2.3%) CFA positive and 14/2,561 (0.6%) Mf positive. No children were Mf positive. However, LF infection was highly heterogeneous; 8 villages (26.7%) had a CFA prevalence >2%, and 7 villages (23.3%) had an Mf prevalence >1%. To identify sentinel villages with LF in areas under-sampled by PPS, 19 additional villages suspected to have LF were sampled, with 15 (79%) having >2% CFA prevalence and 7 (38%) >1% Mf (range 1 – 22%). Twenty-four villages were evaluated before and after MDA in age-matched adults ( ≥ 18 years). Treatment reduced CFA prevalence by 34% and Mf prevalence by 90%. Post-MDA model-based geostatistics efficiently selected an additional 23 villages, of which 20 (87%) had a CFA prevalence > 2%. None of these villages had >1% Mf. Post-MDA, two of four districts had no villages with >1% Mf.

Conclusions

Model-based geostatistics was more effective than PPS in sampling high-risk LF sites in a heterogeneous area. Low LF prevalence and partial reduction of CFA limit children’s effectiveness as sentinels. A single round of high-coverage MDA with IDA achieved elimination targets in low-prevalence villages in PNG. Higher-prevalence areas will need additional MDA rounds, which could be targeted to smaller evaluation units to cut costs.

Trial registration

Clinicaltrials.gov NCT04124250

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AlbendazoleDiethylcarbamazineElephantiasis, FilarialFilaricidesIvermectinMass Drug AdministrationAdolescentAdultAnimalsChildFemaleHumansMaleAntigens, HelminthCross-Sectional StudiesPapua New GuineaPrevalence

Substanzen

AlbendazoleAntigens, HelminthDiethylcarbamazineFilaricidesIvermectin

Autor:innen und Institutionen

  • Department of Pathology, Center for Global Health and Disease, Case Western Reserve University, Cleveland, Ohio, United States of America.
  • Provincial Health Department, Kokopo, East New Britain Province, Papua New Guinea.
  • Papua New Guinea Department of Health, Port Moresby, Papua New Guinea.
  • Papua New Guinea Institute of Medical Research, Goroka, Papua New Guinea.
  • Japan International Cooperation Agency (JICA), Tokyo, Japan.
  • Centre for Health Informatics, Computing and Statistics, Lancaster University, Lancaster, United Kingdom.

ORCID-Profile: Christopher L King

Förderung

  • NCATS NIH HHS
  • Bill and Melinda Gates Foundation
  • National Health and Medical Research Council

Zitieren

APA

Bun, K., Mode, B., Susapu, M., Salo, J., Bjerum, C., Payne, M., Tisch, D., Sekihara, M., Giorgi, E., Weil, G. J., Fischer, P. U., Robinson, L., Laman, M., & King, C. L. (2025). Alternative approaches for monitoring and evaluation of lymphatic filariasis following mass drug treatment with ivermectin, diethylcarbamazine and albendazole in East New Britain Province, Papua New Guinea. PLOS Neglected Tropical Diseases. https://doi.org/10.1371/journal.pntd.0012128

Vancouver

Bun K, Mode B, Susapu M, Salo J, Bjerum C, Payne M, et al. Alternative approaches for monitoring and evaluation of lymphatic filariasis following mass drug treatment with ivermectin, diethylcarbamazine and albendazole in East New Britain Province, Papua New Guinea. PLOS Neglected Tropical Diseases. 2025. doi:10.1371/journal.pntd.0012128

BibTeX
@article{Bun2025,
  author = {Bun, Krufinta and Mode, Benedict and Susapu, Melinda and Salo, Joyceline and Bjerum, Catherine and Payne, Michael and Tisch, Daniel and Sekihara, Makoto and Giorgi, Emanuele and Weil, Gary J and Fischer, Peter U and Robinson, Leanne and Laman, Moses and King, Christopher L},
  title = {Alternative approaches for monitoring and evaluation of lymphatic filariasis following mass drug treatment with ivermectin, diethylcarbamazine and albendazole in East New Britain Province, Papua New Guinea},
  journal = {PLOS Neglected Tropical Diseases},
  year = {2025},
  doi = {10.1371/journal.pntd.0012128}
}
Kostenlos starten →